EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
DETERMINATION UNDER SUBSECTION 85B(1)
No. PB 23 OF 2007
Purpose and operation
1. The purpose of the Australian Pharmaceutical Benefits Scheme (PBS) is to provide timely, reliable and affordable access for the Australian community to necessary and cost-effective medicines.
2. The PBS is regulated by Part VII of the National Health Act 1953 (the Act), which provides for the supply of listed drugs and medicinal preparations as pharmaceutical benefits.
3. “Pharmaceutical benefit” is defined under subsection 84(1) of the Act as a drug or medicinal preparation in relation to which, by virtue of section 85 of the Act, Part VII of the Act applies.
4. Subsection 85B(1) of the Act enables the Minister to determine those pharmaceutical benefits for which there exists a price difference between what the Government is prepared to subsidise and that required by the manufacturer, and to determine in respect of each of those benefits the price to pharmacist which is to be used as a basis for reimbursement and the price to pharmacist sought by the manufacturer. Section 85B is used for special patient contribution items, for the therapeutic group premium policy and for the brand premium policy.
5. The determination sets out the conditions under which subsection 85B(1) applies. The Schedule to the determination lists those pharmaceutical benefits to which subsection 85B(1) applies, the form (strength, type, size etc.), the brand, the pack size, the price to pharmacist that the Government is prepared to pay and the price to pharmacist that the manufacturer requires.
6. The determination made under section 85B(1) of the Act on 14 February 2007 with effect from 1 March 2007 (No. PB 15 of 2007) is repealed and substituted with this determination.
7. This determination is remade to give effect, as from 1 April 2007, to changes to the list of drugs and medicinal preparations available as pharmaceutical benefits, as recommended by the Pharmaceutical Benefits Committee. Changes to the Schedule to this determination are detailed in the attached summary of changes.
Consultations
8. The Pharmaceutical Benefits Advisory Committee (PBAC) is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister for Health and Ageing about which drugs and medicinal preparations should be available as pharmaceutical benefits. Under subsection 101(4) of the Act, a drug or medicinal preparation may not be declared to be a drug or medicinal preparation to which Part VII of the Act applies unless the PBAC has recommended that it be so declared. When recommending a medicine be listed on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.
9. The determination gives effect to recommendations made by the PBAC. PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.
10. Details of the determination are set out in the Attachment.
11. This determination is a legislative instrument for the purposes of the Legislative Instruments Act 2003.
12. The determination was made on 12 March 2007 and commenced on 1 April 2007.
SUMMARY OF CHANGES
Brands to which a special patient contribution now applies |
| |||||
Naratriptan Hydrochloride | Tablet equivalent to 2.5 mg naratriptan (GK) | |||||
Zolmitriptan | Tablet 2.5 mg (AP)
| |||||
Brands to which a brand premium now applies |
| |||||
Sumatriptan Succinate | Tablet 50 mg (GK)
| |||||
Brands with an increased brand premium |
| |||||
Alendronate Sodium | Tablet equivalent to 70 mg alendronic acid (MK) | |||||
Carbamazepine | Tablet 100 mg (NV) | |||||
| Tablet 200 mg (NV) | |||||
Citalopram Hydrobromide | Tablet equivalent to 20 mg citolapram (LU) | |||||
Erythromycin Ethyl Succinate | Tablet equivalent to 400 mg erythromycin (AB) | |||||
Fluvastatin Sodium | Capsule equivalent to 20 mg fluvastatin (NM) | |||||
| Capsule equivalent to 40 mg fluvastatin (NM) | |||||
Metoprolol Tartrate | Tablet 50 mg (NV) | |||||
| Tablet 100 mg (NV) | |||||
Nizatidine | Tablet 150 mg (AS) | |||||
| Tablet 300 mg (AS) | |||||
Paraffin - Soft White with Paraffin - Liquid | Eye ointment, compound, 3.5 g (AQ) | |||||
| Pack containing 2 tubes eye ointment, compound, 3.5 g (AG) | |||||
Pilocarpine Hydrochloride | Eye drops 10 mg per mL, 15 mL (AG) | |||||
| Eye drops 20 mg per mL, 15 mL (AG) | |||||
| Eye drops 40 mg per mL, 15 mL (AG) | |||||
| Eye drops 60 mg per mL, 15 mL (AG) | |||||
Pravastatin Sodium | Tablet 10 mg (BQ) | |||||
| Tablet 20 mg (BQ) | |||||
| Tablet 40 mg (BQ) | |||||
| Tablet 80 mg (BQ) | |||||
Prednisolone | Tablet 1 mg (AS) | |||||
Prednisolone Sodium Phosphate | Oral solution equivalent to 5 mg prednisolone per mL, 30 mL (AS) | |||||
Simvastatin | Tablet 5 mg (FR) | |||||
| Tablet 5 mg (MK) | |||||
| Tablet 10 mg (FR) | |||||
| Tablet 10 mg (MK) | |||||
| Tablet 20 mg (FR) | |||||
| Tablet 20 mg (MK) | |||||
| Tablet 40 mg (FR) | |||||
| Tablet 40 mg (MK) | |||||
| Tablet 80 mg (FR) | |||||
| Tablet 80 mg (MK)
| |||||
Brands with a decreased brand premium |
| |||||
Ciprofloxacin Hydrochloride | Eye drops equivalent to 3 mg ciprofloxacin per mL, 5 mL (AQ) | |||||
Diclofenac Sodium | Tablet 25 mg (enteric coated) (NV) | |||||
| Tablet 50 mg (enteric coated) (NV) | |||||
Ramipril | Capsule 10 mg (AV)
| |||||
Brands to which a brand premium no longer applies (price decrease) |
| |||||
Ramipril | Tablet 1.25 mg (ML) | |||||
| Tablet 2.5 mg (ML) | |||||
| Tablet 5 mg (ML) | |||||
| Capsule 10 mg (ML)
| |||||
Brands with a price change but no change in brand premium |
| |||||
Aspirin | Tablet 100 mg (MX) | |||||
Cimetidine | Tablet 200 mg (GK) | |||||
| Tablet 400 mg (GK) | |||||
Glyceryl Trinitrate | Tablet 600 micrograms, 100 (SI) | |||||
Potassium Chloride | Tablet 600 mg (sustained release) (NV) | |||||
Potassium Chloride with Potassium Bicarbonate | Tablet, effervescent, 14 mmol K+ and 8 mmol CI- (AS) | |||||
Prednisone | Tablet 1 mg (AS)
| |||||
Brands to which a therapeutic group premium no longer applies (price decrease) |
| |||||
Ramipril | Pack containing 7 tablets 2.5 mg, 21 tablets 5 mg and 10 capsules 10 mg (AV)
| |||||
Brands with a price change but no change in therapeutic group premium |
| |||||
Lansoprazole | Sachet containing granules for oral suspension, 30 mg per sachet (WY) | |||||
ATTACHMENT
Paragraph 1 provides that this determination commences on 1 April 2007.
Paragraph 2 provides that the determination under subsection 85B(1) of the National Health Act 1953 made on 14 February 2007 (No. PB 15 of 2007) is repealed.
Paragraph 3 defines the term “authority prescription”.
Paragraph 4 provides that the Schedule to the determination lists those brands of pharmaceutical benefits to which subsection 85B(1) apply.
Paragraph 5 provides that where a form and brand of pharmaceutical benefit is listed in Part A of the Schedule, Part B of the Schedule lists the quantity or number of units that is to be used for determining the manufacturer’s price for sales, and the price claimed by the manufacturer, for that form and brand.
Paragraph 6 provides that Part C of the Schedule lists the manufacturer’s price for sales for a particular form and brand that is listed in Part A of the Schedule.
Paragraph 7 provides that Part D of the Schedule lists the price claimed by the manufacturer for a particular form and brand that is listed in Part A of the Schedule.
Paragraph 8 lists those pharmaceutical benefits for which section 85B of the Act will not apply, if the prescription was written before 1 April 2007 and the pharmaceutical benefit is supplied before 1 June 2007.
Paragraph 9 lists the names of the manufacturers of those brands of pharmaceutical benefits, listed under “Brand” in Part A of the Schedule, to which this determination applies.
The Schedule to the determination lists those pharmaceutical benefits to which subsection 85B(1) applies, the form (strength, type, size etc.), the brand, the pack size, the price to pharmacist that the Government is prepared to pay and the price to pharmacist that the manufacturer requires.